NASDAQ:HBIO

Harvard Bioscience (HBIO) Stock Price, News & Analysis

$3.56
-0.13 (-3.52%)
(As of 04/25/2024 ET)
Today's Range
$3.47
$3.70
50-Day Range
$3.69
$4.86
52-Week Range
$3.47
$6.29
Volume
65,305 shs
Average Volume
85,058 shs
Market Capitalization
$154.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Harvard Bioscience MarketRank™ Stock Analysis

Analyst Rating
0.00 Rating Score
Upside/​Downside
96.6% Upside
$7.00 Price Target
Short Interest
Bearish
1.55% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.18
Upright™ Environmental Score
News Sentiment
0.15mentions of Harvard Bioscience in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.50 out of 5 stars

Computer And Technology Sector

298th out of 586 stocks

Analytical Instruments Industry

10th out of 26 stocks

HBIO stock logo

About Harvard Bioscience Stock (NASDAQ:HBIO)

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

HBIO Stock Price History

HBIO Stock News Headlines

Mysterious Gold Leverage Just Announced
World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.
Harvard man pleads guilty to assault
Mysterious Gold Leverage Just Announced
World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.
Harvard’s applications drop amid campus scandals
See More Headlines
Receive HBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harvard Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:HBIO
CUSIP
41690610
Employees
391
Year Founded
1901

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$7.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+95.5%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-3,410,000.00
Pretax Margin
-2.28%

Debt

Sales & Book Value

Annual Sales
$112.25 million
Cash Flow
$0.22 per share
Book Value
$1.71 per share

Miscellaneous

Free Float
39,493,000
Market Cap
$155.37 million
Optionable
Optionable
Beta
1.42

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

HBIO Stock Analysis - Frequently Asked Questions

What is Harvard Bioscience's stock price target for 2024?

0 Wall Street research analysts have issued 1 year price objectives for Harvard Bioscience's stock. Their HBIO share price targets range from $7.00 to $7.00. On average, they expect the company's share price to reach $7.00 in the next year. This suggests a possible upside of 96.6% from the stock's current price.
View analysts price targets for HBIO
or view top-rated stocks among Wall Street analysts.

How have HBIO shares performed in 2024?

Harvard Bioscience's stock was trading at $5.35 at the start of the year. Since then, HBIO stock has decreased by 33.5% and is now trading at $3.56.
View the best growth stocks for 2024 here
.

Are investors shorting Harvard Bioscience?

Harvard Bioscience saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 673,000 shares, an increase of 5.7% from the March 31st total of 636,700 shares. Based on an average trading volume of 86,900 shares, the short-interest ratio is presently 7.7 days.
View Harvard Bioscience's Short Interest
.

How were Harvard Bioscience's earnings last quarter?

Harvard Bioscience, Inc. (NASDAQ:HBIO) announced its earnings results on Thursday, March, 7th. The medical instruments supplier reported $0.01 EPS for the quarter, missing analysts' consensus estimates of $0.03 by $0.02. The medical instruments supplier earned $28.15 million during the quarter, compared to analyst estimates of $27.80 million. Harvard Bioscience had a negative net margin of 3.04% and a positive trailing twelve-month return on equity of 2.75%.

What other stocks do shareholders of Harvard Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harvard Bioscience investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), NVIDIA (NVDA), LightPath Technologies (LPTH), Micron Technology (MU), Nokia Oyj (NOK), Evoke Pharma (EVOK), General Electric (GE) and Gilead Sciences (GILD).

How do I buy shares of Harvard Bioscience?

Shares of HBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Harvard Bioscience have any subsidiaries?
The following companies are subsidiares of Harvard Bioscience: Data Sciences International.
Read More
This page (NASDAQ:HBIO) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners